Chapter 17: Adaptive Immunity - Specific Defenses of the Host

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/44

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary flashcards covering the components, mechanisms, cells, antibodies, cytokines, and forms of adaptive immunity from Chapter 17.

45 Terms

1
New cards

Innate Immunity

Nonspecific host defenses that act against any pathogen regardless of its identity.

2
New cards

Adaptive Immunity

Host defenses characterized by induced resistance and specific targeting of a particular pathogen, divided into humoral and cell-mediated immunity.

3
New cards

Humoral Immunity

The branch of adaptive immunity mediated by B-lymphocytes and antibodies that primarily targets extracellular pathogens and toxins.

4
New cards

Cell-Mediated Immunity

The branch of adaptive immunity governed by T-lymphocytes that acts primarily against intracellular pathogens, infected host cells, and cancer cells.

5
New cards

B-Lymphocytes (B Cells)

Lymphocytes that develop from stem cells in red bone marrow or fetal liver, mature in adult red bone marrow, and differentiate into antibody-producing plasma cells and memory cells.

6
New cards

T-Lymphocytes (T Cells)

Lymphocytes that originate from stem cells in bone marrow or fetal liver and migrate to mature in the thymus, functioning as helper, cytotoxic, regulatory, or memory cells.

7
New cards

Plasma Cells

Effector B cells that synthesize and secrete large quantities of antibodies into the bloodstream.

8
New cards

Memory Cells

Long-lived lymphocytes formed during an immune response that persist in lymphoid tissues or circulation to mount a rapid and potent response upon subsequent antigen exposure.

9
New cards

Cytokines

Soluble chemical messengers comprising over 200 distinct proteins that mediate intercellular communication, activation, and regulation across the immune system.

10
New cards

Interleukins (ILs)

Cytokines that stimulate cell proliferation, maturation, migration, or activation among immune response cells.

11
New cards

Chemokines

A family of cytokines secreted by cells such as macrophages and epithelial cells to direct the chemotaxis of leukocytes (e.g., neutrophils) toward sites of infection.

12
New cards

Tumor Necrosis Factor-Alpha (TNF-α\text{TNF-}\alpha)

A cytokine produced by macrophages, THT_H cells, and NK cells that acts on tumor cells and plays a major role in triggering inflammation.

13
New cards

Gamma Interferon (IFN-γ\text{IFN-}\gamma)

A cytokine produced by TH1T_H1 cells that promotes phagocytosis, activates macrophages, and enhances the humoral immune response.

14
New cards

Antigen (Ag)

A foreign substance that induces the host body to generate specific antibodies or sensitized T cells.

15
New cards
<p>Epitope (Antigenic Determinant)</p>

Epitope (Antigenic Determinant)

A specific structural component or surface site on an antigen that directly binds to a complementary antigen-binding site on an antibody or T-cell receptor.

16
New cards

Hapten

A low-molecular-weight substance (e.g., penicillin) that cannot stimulate antibody formation by itself unless conjugated to a larger carrier molecule.

17
New cards

Immunoglobulin (Ig)

A globular protein consisting of two identical heavy chains and two identical light chains joined by disulfide bonds, featuring variable (V) antigen-binding sites and a constant (C) Fc stem region.

<p>A globular protein consisting of two identical heavy chains and two identical light chains joined by disulfide bonds, featuring variable (V) antigen-binding sites and a constant (C) Fc stem region.</p>
18
New cards

IgG Antibodies

Monomeric antibodies accounting for 80%80\% of serum immunoglobulins that fix complement, cross the placenta and tissue barriers, enhance phagocytosis, neutralize toxins and viruses, and protect the fetus and newborn.

19
New cards
<p>IgM Antibodies</p>

IgM Antibodies

Pentameric antibodies linked by a J chain that make up 5–10%5\text{--}10\% of serum immunoglobulins; they fix complement, agglutinate microbes, serve as the first antibody class produced during an infection, and signal an active, current infection.

20
New cards
<p>IgA Antibodies</p>

IgA Antibodies

Dimeric antibodies containing a J chain and a secretory component that constitute 10–15%10\text{--}15\% of serum immunoglobulins; found in tears, saliva, and breast milk, providing mucosal and infant GI protection.

21
New cards

IgD Antibodies

Monomeric antibodies making up 0.2%0.2\% of serum immunoglobulins located in blood, lymph, and on the surface of B cells, where they assist in initiating immune responses.

22
New cards

IgE Antibodies

Monomeric antibodies comprising 0.002%0.002\% of serum immunoglobulins that bind to mast cells and basophils, inducing histamine release during allergic reactions (erythema) and aiding in the lysis of parasitic worms.

23
New cards
<p>Agglutination</p>

Agglutination

The clumping of antigens together by antibodies, which reduces the total number of infectious units the immune system must clear.

24
New cards
<p>Opsonization</p>

Opsonization

The process of coating an antigen with antibodies to enhance its ingestion by phagocytic cells.

25
New cards
<p>Complement Fixation (Classical Pathway)</p>

Complement Fixation (Classical Pathway)

The activation of complement proteins initiated by antigen-antibody immune complexes, leading to inflammation and microbial cell lysis.

26
New cards
<p>Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)</p>

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Destruction of a large target cell (such as a parasite) coated with antibodies by effector cells like macrophages, eosinophils, and NK cells through the release of perforin and lytic enzymes.

27
New cards
<p>Neutralization</p>

Neutralization

The binding of antibodies to viruses, bacteria, or exotoxins that blocks their adhesion to host mucosa or prevents attachment to receptor sites.

28
New cards
<p>T-Independent Antigen</p>

T-Independent Antigen

A repeating antigen (typically a polysaccharide) that can directly cross-link B-cell receptors to activate the B cell without T helper assistance, generating IgM only and producing no memory cells.

29
New cards

T-Dependent Antigen

An antigen that requires uptake and processing by antigen-presenting cells, presentation via MHC class II, and cytokine signals from CD4+CD4^+ T helper cells to stimulate full B-cell activation, class switching, and memory cell generation.

30
New cards

Major Histocompatibility Complex Class I (MHC I)

Cell-surface glycoproteins expressed on all nucleated cells that present altered endogenous antigens (from viral infection or cancer) to CD8+CD8^+ cytotoxic T cells.

31
New cards

Major Histocompatibility Complex Class II (MHC II)

Cell-surface glycoproteins present specifically on antigen-presenting cells (APCs) that display processed exogenous peptide fragments to CD4+CD4^+ T helper cells.

32
New cards

Antigen-Presenting Cells (APCs)

Immune cells—specifically dendritic cells, macrophages, and B cells—that internalize foreign antigens, digest them into peptides, and present them bound to MHC II complexes.

33
New cards

Clonal Selection

The proliferation and differentiation of a specific B or T lymphocyte clone following the precise recognition of its complementary antigen.

34
New cards

CD4+CD4^+ T Helper (THT_H) Cells

T lymphocytes that recognize antigen fragments presented with MHC class II on APCs and secrete cytokines required to activate B cells, cytotoxic T lymphocytes, and macrophages.

35
New cards

CD8+CD8^+ Cytotoxic T Lymphocytes (CTLs)

Effector T cells activated by binding endogenous antigens on MHC class I that destroy virus-infected, cancerous, or transplanted cells by inducing apoptosis.

<p>Effector T cells activated by binding endogenous antigens on MHC class I that destroy virus-infected, cancerous, or transplanted cells by inducing apoptosis.</p>
36
New cards

Perforin

A pore-forming protein secreted by cytotoxic T lymphocytes that creates transmembrane holes in target cell membranes.

37
New cards

Granzymes

Proteolytic enzymes released by cytotoxic T lymphocytes that enter infected target cells via perforin pores to trigger apoptosis.

38
New cards

T Regulatory (TregT_{reg}) Cells

Specialized T lymphocytes that suppress other T-cell responses against self-antigens to maintain immune tolerance and prevent autoimmune disorders.

39
New cards

Antibody Titer

A measurable laboratory index reflecting the amount or relative concentration of specific antibodies present in blood serum.

40
New cards

Primary Immune Response

The adaptive immune reaction following initial antigen exposure, characterized by a latent period of at least a week, a rise in IgM followed by IgG, and development of clonal memory cells.

41
New cards
<p>Secondary (Memory) Immune Response</p>

Secondary (Memory) Immune Response

A rapid, robust immune response triggered upon re-exposure to a known antigen, characterized by immediate and high-level production of IgG driven by memory cells.

42
New cards

Naturally Acquired Active Immunity

Immunity that develops when pathogens or antigens enter the body naturally during infection, prompting the host to produce antibodies and sensitized lymphocytes.

43
New cards

Naturally Acquired Passive Immunity

Short-term immunity acquired naturally when antibodies transfer from mother to fetus across the placenta (IgG) or to an infant through breast milk (IgA).

44
New cards

Artificially Acquired Active Immunity

Immunity stimulated by administering prepared antigens through vaccines, inducing the recipient's immune system to form antibodies and specific memory lymphocytes.

45
New cards

Artificially Acquired Passive Immunity

Temporary protection achieved by injecting preformed antibodies derived from an immune donor or serum (such as monoclonal antibody treatments) into a patient.

<p>Temporary protection achieved by injecting preformed antibodies derived from an immune donor or serum (such as monoclonal antibody treatments) into a patient.</p>